Back to top
more

atai Life Sciences (ATAI)

(Delayed Data from NSDQ)

$4.26 USD

4.26
7,344,777

+0.09 (2.16%)

Updated Aug 4, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?

by Zacks Equity Research

Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice

by Zacks Equity Research

Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how atai Life Sciences N.V. (ATAI) and Novartis (NVS) have performed compared to their sector so far this year.

Zacks Equity Research

atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know

by Zacks Equity Research

Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Zacks Equity Research

Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how atai Life Sciences N.V. (ATAI) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks Equity Research

LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

LifeStance Health (LFST) delivered earnings and revenue surprises of 50% and 4.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Option Care (OPCH) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Option Care (OPCH) delivered earnings and revenue surprises of 6.06% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Cigna Group (CI) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Cigna (CI) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.

Zacks Equity Research

atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice

by Zacks Equity Research

Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Align Technology (ALGN) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.

Zacks Equity Research

Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aveanna (AVAH) delivered earnings and revenue surprises of 50% and 3.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

LifeStance Health (LFST) delivered earnings and revenue surprises of -33.33% and 6.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Elevance Health (ELV) & Verizon Partner to Bring Health Equity

by Zacks Equity Research

Elevance Health (ELV) launches a new program with an Affordable Connectivity Program offering free smartphones to eligible members.

Zacks Equity Research

Brookdale (BKD) Sees Growth in December 2023 Occupancy Volumes

by Zacks Equity Research

Brookdale (BKD) witnesses a continuous streak of 26 months of year-over-year increases in the weighted average occupancy level.

Zacks Equity Research

Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now

by Zacks Equity Research

Improving membership levels, strategic acquisitions, expanding government business, improving operating margin and solid growth outlook poise UnitedHealth Group (UNH) well for growth.

Zacks Equity Research

Elevance Health (ELV) Enhances Whole Health With Paragon Buyout

by Zacks Equity Research

Elevance Health (ELV) agrees to acquire Paragon Healthcare, boosting its capabilities in specialty pharmacy.

Zacks Equity Research

Here's Why You Should Retain Teladoc (TDOC) Stock for Now

by Zacks Equity Research

Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.

Sanghamitra Saha headshot

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include DouYu International (DOYU), Regis (RGS), 2seventy bio Inc. (TSVT), atai Life Sciences (ATAI) and GameStop (GME).

Zacks Equity Research

UnitedHealth Group's (UNH) Brazil Unit Draws Buyout Interests

by Zacks Equity Research

UnitedHealth Group (UNH) expects to divest its troubled Brazil business, enhancing its overall results.

Zacks Equity Research

UnitedHealth Group's (UNH) Arm Launches OptumRx Weight Engage

by Zacks Equity Research

UnitedHealth Group (UNH) enhances Optum Rx's offerings with the launch of the Weight Engage program.

Zacks Equity Research

Brookdale's (BKD) November 2023 Weighted Average Occupancy Up

by Zacks Equity Research

Brookdale (BKD) witnesses 25 straight months of year-over-year increase in weighted average occupancy level.